Faeth Therapeutics holder cuts stake to 0.0%

Faeth Therapeutics, Inc. received an amended ownership report from StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross.

Rhea-AI Filing Summary

Faeth Therapeutics, Inc. received an amended ownership report from StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross. These reporting persons now state they beneficially own 0 shares of Faeth Therapeutics common stock, representing 0.0% of the class.

The percentage is calculated using 25,778,754 shares of common stock reported as issued and outstanding as of June 15, 2026. The amendment confirms they have no sole or shared voting or dispositive power over any shares and that they hold 5 percent or less of the class under Schedule 13G rules.

Key Figures

Beneficial ownership: 0 shares Ownership percentage: 0.0% Shares outstanding: 25,778,754 shares

3 metrics

Beneficial ownership 0 shares Common Stock, $0.0001 par value per share

Ownership percentage 0.0% Percent of Faeth Therapeutics common stock class

Shares outstanding 25,778,754 shares Issued and outstanding as of June 15, 2026, per Form 8-K

Key Terms

beneficial owner, dispositive power, Schedule 13G, Joint Filing Agreement

4 terms

beneficial owner financial

"Each Reporting Person may be deemed to be the beneficial owner of 0 shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

dispositive power financial

"Sole Dispositive Power 0.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"Ownership of 5 percent or less of a class "

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Joint Filing Agreement regulatory

"Exhibit Information JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Schedule 13G/A mean for Faeth Therapeutics (FTH)?

The amendment reports that StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross now beneficially own 0 shares of Faeth Therapeutics common stock, representing 0.0% of the class, indicating they are no longer significant shareholders under 13G thresholds.

How many Faeth Therapeutics (FTH) shares are outstanding in this filing?

The reporting persons calculate their ownership based on 25,778,754 shares of Faeth Therapeutics common stock, reported as issued and outstanding as of June 15, 2026 in a Form 8-K filed on June 18, 2026.

Who are the reporting persons in this Faeth Therapeutics (FTH) Schedule 13G/A?

The filing is jointly submitted by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross, collectively referred to as the reporting persons, with a business address at 520 Madison Avenue, 19th Floor, New York, NY 10022.

What voting and dispositive power do the reporting persons hold over Faeth Therapeutics (FTH) shares?

Each reporting person reports 0 sole voting power, 0 shared voting power, 0 sole dispositive power, and 0 shared dispositive power, confirming they do not control voting or disposition of any Faeth Therapeutics common shares.

Why does the Faeth Therapeutics (FTH) filing reference ownership of 5 percent or less?

Item 5 states the reporting persons’ ownership of 5 percent or less of the class. With beneficial ownership at 0.0%, they fall below the 5% threshold that typically triggers more substantial Schedule 13D or 13G reporting obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 12:00 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Faeth Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

81728A207

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

StemPoint Capital LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

StemPoint Capital Management GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: StemPoint Capital Management GP LLC is a limited liability company.

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

Michelle Ross

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Faeth Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 701 Tillery Street #12 #1010, Austin, TX 78702
Item 2.
(a)	Name of person filing: This filing is being jointly filed by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons" and each a "Reporting Person").
(b)	Address or principal business office or, if none, residence: The business addresses of each Reporting Person is: 520 Madison Avenue, 19th Floor New York, NY 10022
(c)	Citizenship: StemPoint Capital LP is a limited partnership organized under the laws of the State of Delaware. StemPoint Capital Management GP LLC is a limited liability company organized under the laws of the State of Delaware. Michelle Ross is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 81728A207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Items 5-9 of each cover page are incorporated by reference. Each Reporting Person may be deemed to be the beneficial owner of 0 shares of Common Stock, $0.0001 par value per share (the "Common Stock").
(b)	Percent of class: Each Reporting Person may be deemed to beneficially own 0.0% shares of Common Stock, which is calculated based on 25,778,754 shares of Common Stock reported as issued and outstanding as of June 15, 2026, in Form 8-K filed with the Securities and Exchange Commission on June 18, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: -0-
	(ii) Shared power to vote or to direct the vote: 0.
	(iii) Sole power to dispose or to direct the disposition of: -0-
	(iv) Shared power to dispose or to direct the disposition of: 0.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

StemPoint Capital LP

Signature:	/s/ Sean C. Tan
Name/Title:	Sean C. Tan, Authorized Signatory
Date:	08/14/2026

StemPoint Capital Management GP LLC

Signature:	/s/ Sean C. Tan
Name/Title:	Sean C. Tan, Authorized Signatory
Date:	08/14/2026

Michelle Ross

Signature:	/s/ Michelle Ross
Name/Title:	Michelle Ross
Date:	08/14/2026

Exhibit Information

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)